Rigel Pharmaceuticals
RIGL
106 hedge funds and large institutions have $115M invested in Rigel Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 17 closing their positions.
886% more call options, than puts
Call options by funds: $887K | Put options by funds: $90K
0% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 34
0.28% less ownership
Funds ownership: 6.37% → 6.09% (-0.28%)
10% less funds holding
Funds holding: 118 → 106 (-12)
20% less capital invested
Capital invested by funds: $143M → $115M (-$28M)
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.75M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$1.39M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$752K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$737K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$264K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.49M |
| 2 |
Two Sigma Investments
New York
|
-$1.79M |
| 3 |
Millennium Management
New York
|
-$1.66M |
| 4 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$1.61M |
| 5 |
Two Sigma Advisers
New York
|
-$1.4M |
RIGL Hedge Fund Activity: Q3 2023 in Review
106 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2023, worth a combined $115M — down 20% from $143M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RIGL and 6 opened new positions — a net loss of 11 holders — while 34 trimmed existing stakes and 34 added.
The largest buyer was Morgan Stanley, adding an estimated $3.75M. The largest seller was Vanguard Group, cutting an estimated $2.49M.
- 106 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2023, down from 118 in Q2 2023.
- Funds reported $115M of Rigel Pharmaceuticals stock for Q3 2023, down 20% quarter-over-quarter.
- 6 funds opened new Rigel Pharmaceuticals positions in Q3 2023 and 17 closed out, a net change of -11 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2023 was Morgan Stanley, an estimated $3.75M added.
- The largest Rigel Pharmaceuticals seller in Q3 2023 was Vanguard Group, an estimated $2.49M sold.
Based on aggregated 13F filings for Q3 2023.